Litigation
Mylan Pharmaceuticals Inc. v. Merck Sharp & Dohme Corp.
final written decision; claims not unpatentableIPR2020-00040
Auto-generating section 1 of 4: Case overview & background…
Each section takes ~30-60s with web-search grounding. Keep this tab open — sections will fill in below as they complete.
- Filed
- 2019-10-30
- Terminated
- 2021-05-07
Patents at issue (1)
Plaintiffs (1)
Defendants (1)
Summary
Inter partes review petition filed Oct. 30, 2019 and instituted May 12, 2020. Final Written Decision on May 7, 2021 found no challenged claims (1–4, 17, 19, 21–23) unpatentable. Dr. Reddy's joined via IPR2020-01060 and Sun via IPR2020-01072.
Case overview & background
Plain-language overview of the case: parties, accused product, patents at issue, and why the suit matters.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Key legal developments & outcome
Major rulings, motions, claim construction, settlements, and the present posture or final disposition.
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Plaintiff representatives
Counsel of record for the plaintiff(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).
Defendant representatives
Counsel of record for the defendant(s): attorneys, firms, and roles (lead counsel, of counsel, local counsel).
Not yet generated. Click Generate to run the LLM with web-search grounding (~30-60s).